Romania · Delayed Price · Currency is RON Antibiotice Statistics
Total Valuation
Antibiotice has a market cap or net worth of RON 1.20 billion. The enterprise value is 1.42 billion.
| Market Cap | 1.20B |
| Enterprise Value | 1.42B |
Important Dates
The next confirmed earnings date is Wednesday, May 27, 2026.
| Earnings Date | May 27, 2026 |
| Ex-Dividend Date | Oct 1, 2026 |
Share Statistics
Antibiotice has 671.34 million shares outstanding.
| Current Share Class | 671.34M |
| Shares Outstanding | 671.34M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.12% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.69% |
| Float | 227.94M |
Valuation Ratios
The trailing PE ratio is 23.11.
| PE Ratio | 23.11 |
| Forward PE | n/a |
| PS Ratio | 1.81 |
| PB Ratio | 1.28 |
| P/TBV Ratio | 1.32 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 16.51 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.39, with an EV/FCF ratio of -20.29.
| EV / Earnings | 27.50 |
| EV / Sales | 2.16 |
| EV / EBITDA | 11.39 |
| EV / EBIT | 20.11 |
| EV / FCF | -20.29 |
Financial Position
The company has a current ratio of 2.02, with a Debt / Equity ratio of 0.25.
| Current Ratio | 2.02 |
| Quick Ratio | 1.27 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | 1.90 |
| Debt / FCF | -3.38 |
| Interest Coverage | 15.85 |
Financial Efficiency
Return on equity (ROE) is 5.67% and return on invested capital (ROIC) is 5.24%.
| Return on Equity (ROE) | 5.67% |
| Return on Assets (ROA) | 3.31% |
| Return on Invested Capital (ROIC) | 5.24% |
| Return on Capital Employed (ROCE) | 6.20% |
| Weighted Average Cost of Capital (WACC) | 5.11% |
| Revenue Per Employee | 487,115 |
| Profits Per Employee | 38,206 |
| Employee Count | 1,356 |
| Asset Turnover | 0.49 |
| Inventory Turnover | 1.46 |
Taxes
In the past 12 months, Antibiotice has paid 8.38 million in taxes.
| Income Tax | 8.38M |
| Effective Tax Rate | 13.93% |
Stock Price Statistics
The stock price has decreased by -12.88% in the last 52 weeks. The beta is 0.28, so Antibiotice's price volatility has been lower than the market average.
| Beta (5Y) | 0.28 |
| 52-Week Price Change | -12.88% |
| 50-Day Moving Average | 1.95 |
| 200-Day Moving Average | 2.34 |
| Relative Strength Index (RSI) | 34.12 |
| Average Volume (20 Days) | 304,485 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Antibiotice had revenue of RON 660.04 million and earned 51.77 million in profits. Earnings per share was 0.08.
| Revenue | 660.04M |
| Gross Profit | 400.50M |
| Operating Income | 70.77M |
| Pretax Income | 60.15M |
| Net Income | 51.77M |
| EBITDA | 124.98M |
| EBIT | 70.77M |
| Earnings Per Share (EPS) | 0.08 |
Balance Sheet
The company has 9.94 million in cash and 237.05 million in debt, with a net cash position of -227.11 million or -0.34 per share.
| Cash & Cash Equivalents | 9.94M |
| Total Debt | 237.05M |
| Net Cash | -227.11M |
| Net Cash Per Share | -0.34 |
| Equity (Book Value) | 932.07M |
| Book Value Per Share | 1.39 |
| Working Capital | 255.33M |
Cash Flow
In the last 12 months, operating cash flow was 72.44 million and capital expenditures -142.61 million, giving a free cash flow of -70.17 million.
| Operating Cash Flow | 72.44M |
| Capital Expenditures | -142.61M |
| Depreciation & Amortization | 54.20M |
| Net Borrowing | 92.51M |
| Free Cash Flow | -70.17M |
| FCF Per Share | -0.10 |
Margins
Gross margin is 60.68%, with operating and profit margins of 10.72% and 7.84%.
| Gross Margin | 60.68% |
| Operating Margin | 10.72% |
| Pretax Margin | 9.11% |
| Profit Margin | 7.84% |
| EBITDA Margin | 18.93% |
| EBIT Margin | 10.72% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.04, which amounts to a dividend yield of 1.97%.
| Dividend Per Share | 0.04 |
| Dividend Yield | 1.97% |
| Dividend Growth (YoY) | -3.31% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 30.81% |
| Buyback Yield | n/a |
| Shareholder Yield | 1.96% |
| Earnings Yield | 4.33% |
| FCF Yield | -5.87% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 13, 2013. It was a forward split with a ratio of 1.1819213313.
| Last Split Date | May 13, 2013 |
| Split Type | Forward |
| Split Ratio | 1.1819213313 |
Scores
Antibiotice has an Altman Z-Score of 3.61 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.61 |
| Piotroski F-Score | 5 |